ARTV
Artiva Biotherapeutics, Inc.Company Information
- Company Name
- Artiva Biotherapeutics, Inc.
- CIK
- CIK0001817241
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ARTV: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ARTV
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-31
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 8,417,933
- Shares sold (TTM)
- 201,927
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 40,363,621
- Shares outstanding
- 39,413,236
- Ownership
- 102.41%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -4.23%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 301 | 21 | 27 | 26 | 28 | 30 | 40 | 56 | 34 | ||||||
| Short Term Investments | 48 | 66 | 81 | 97 | 114 | 136 | 145 | 91 | 12 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | 0 | 1 | 1 | ||||||
| Other Receivables Net Current | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 5 | 6 | 7 | 4 | 3 | 3 | 2 | ||||||
| Assets Current | 352 | 89 | 113 | 130 | 149 | 170 | 189 | 151 | 50 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 6 | 6 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | ||||||
| Operating Lease Right Of Use Asset | 9 | 10 | 11 | 11 | 13 | 13 | 14 | 14 | 15 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | - | - | - | - | - | - | - | - | 3 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | 53 | - | ||||||
| Other Assets Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 369 | 106 | 131 | 149 | 169 | 191 | 210 | 226 | 76 | ||||||
Liabilities Current | |||||||||||||||
| Accounts Payable Current | 1 | 2 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 10 | 6 | 10 | 7 | 6 | 6 | 7 | 8 | 6 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Finance Lease Liability Current | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Current | - | - | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Liabilities Current | 15 | 11 | 13 | 11 | 11 | 12 | 12 | 13 | 11 | ||||||
| Operating Lease Liability Noncurrent | 7 | 7 | 8 | 9 | 10 | 10 | 11 | 11 | 12 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | - | - | 28 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities | 21 | 18 | 21 | 20 | 20 | 22 | 23 | 25 | 51 | ||||||
Stockholders Equity | |||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Additional Paid In Capital Common Stock | 727 | 442 | 440 | 439 | 437 | 436 | 433 | 431 | 22 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | - | -0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -379 | -354 | -331 | -310 | -288 | -267 | -247 | -231 | -213 | ||||||
| Stockholders Equity | 348 | 88 | 110 | 129 | 149 | 169 | 187 | 201 | -191 | ||||||
| Liabilities And Stockholders Equity | 369 | 106 | 131 | 149 | 169 | 191 | 210 | 226 | 76 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Common Stock Shares Authorized | - | - | - | - | - | - | - | - | 700 | ||||||
| Common Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialArtiva Biotherapeutics, Inc. (ARTV) — SEC Financial Statements & Analysis
Artiva Biotherapeutics, Inc. (ARTV) is a biological products, (no diagnostic substances) company, incorporated in DE. Artiva Biotherapeutics, Inc. trades on Nasdaq as: ARTV. Artiva Biotherapeutics, Inc. (ARTV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Artiva Biotherapeutics, Inc. carries a market cap of $382.31M, a P/E ratio of -4.21x, a P/B ratio of 1.10x, a P/S ratio of 146.66x, an enterprise value of $80.39M, and an EV/EBITDA multiple of -0.86x. On profitability, it posts an operating margin of -38276.10%, a net margin of -35496.02%, a Return on Equity (ROE) of -36.58%, a Return on Assets (ROA) of -33.76%, and a Return on Invested Capital (ROIC) of -115.97%. Per share, it reports EPS of $-2.30, diluted EPS of $-2.30, free cash flow per share of $-1.95, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 1.94% year-over-year, and EPS growth of -36.95% year-over-year. On the balance sheet, it maintains a current ratio of 24.16x, a quick ratio of 23.97x, working capital of $337.69M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, free cash flow of $-76.91M (TTM), and net debt of $-301.92M. Figures sourced from SEC EDGAR.
- Market Cap
- $382.31M
- P/E TTM
- -4.21x
- EPS TTM
- $-2.30
- P/B TTM
- 1.10x
- ROE TTM
- -36.58%
- ROA TTM
- -33.76%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-76.91M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Artiva Biotherapeutics, Inc. in?
Artiva Biotherapeutics, Inc. (ARTV) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ARTV trade on?
Artiva Biotherapeutics, Inc. (ARTV) trades on the Nasdaq.
Where is Artiva Biotherapeutics, Inc. incorporated?
Artiva Biotherapeutics, Inc. is incorporated in DE.
When was Artiva Biotherapeutics, Inc. (ARTV)'s most recent SEC filing?
Artiva Biotherapeutics, Inc. (ARTV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ARTV's market cap?
Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $382.31M as of 2026-06-30.
What is ARTV's EPS (earnings per share)?
Artiva Biotherapeutics, Inc. (ARTV)'s trailing twelve month EPS is $-2.30 as of 2026-06-30.
What is ARTV's ROE (return on equity)?
Artiva Biotherapeutics, Inc. (ARTV)'s trailing twelve month Return on Equity (ROE) is -36.58% as of 2026-06-30.
What is ARTV's ROA (return on assets)?
Artiva Biotherapeutics, Inc. (ARTV)'s trailing twelve month Return on Assets (ROA) is -33.76% as of 2026-06-30.
What is ARTV's ROIC (return on invested capital)?
Artiva Biotherapeutics, Inc. (ARTV)'s trailing twelve month Return on Invested Capital (ROIC) is -115.97% as of 2026-06-30.
What is ARTV's EV/EBITDA?
Artiva Biotherapeutics, Inc. (ARTV)'s trailing twelve month EV/EBITDA is -0.86x as of 2026-06-30.